Common Side Effects of Vascepa
Vascepa (icosapent ethyl), used to lower triglycerides, causes joint pain in about 3% of patients, higher than placebo (2%). Gout occurs in 1.1% versus 0.9% on placebo. Other frequent effects include constipation, edema, and atrial fibrillation, typically mild.[1]
Side Effects in Combination Therapy
Vascepa is often combined with statins like atorvastatin or rosuvastatin for cardiovascular risk reduction. No unique adverse effects emerge from these pairings in trials like REDUCE-IT, but risks amplify:
- Increased bleeding: Vascepa mildly raises hemorrhage risk (2.7% vs 2.1% placebo); with anticoagulants or antiplatelets (e.g., aspirin), this rises to 3.6%.[1][2]
- Muscle pain: Statin combos report myalgia in 5-10%, potentially overlapping Vascepa's arthralgia.[3]
- Liver enzyme elevation: Rare (<1%), but monitor with statins.[1]
Serious Risks and Warnings
- Bleeding: Higher doses or with blood thinners increase major events like intracranial hemorrhage (0.5% risk).[1]
- Atrial fibrillation: 5.3% incidence, leading to hospitalization or death in 0.3%; avoid in unstable arrhythmias.[2]
- Heart rhythm issues: Prolongs QT interval; caution with other QT-prolongers.[1]
- Allergic reactions: Rash, anaphylaxis in <1%; stop if severe.[3]
FDA black box warns of heightened atrial fibrillation and bleeding with use.[2]
Patient Factors Raising Risks
Diabetes patients see more atrial fibrillation (7.2% vs 4.6%). Elderly (>65) face higher gout and bleeding. Avoid in hepatic impairment; pregnancy category C due to fetal risks in animal studies.[1][3]
How Effects Differ from Pure EPA/DHA Fish Oil
Unlike OTC fish oils, Vascepa is pure EPA, avoiding DHA-linked LDL increases. Yet, it carries similar but targeted CV risks without broad omega-3 benefits.[1]
Sources
[1]: Vascepa Prescribing Information (Amarin)
[2]: FDA Label for Vascepa
[3]: Drugs.com - Vascepa Side Effects